Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"InveniAI","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"InveniAI","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"InveniAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery"},{"orgOrder":0,"company":"InveniAI","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by InveniAI

    Menu

    InveniAI

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              InveniAI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets

              Details:

              Through collaboration, InveniAI will identify novel therapeutic targets in multiple diseases specified by Ono by leveraging InveniAI's AlphaMeld and ChatAlphaMeld, its AI drug discovery platforms including cutting-edge technologies.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Ono Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InveniAI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence

              Details:

              Under the terms of the Collaboration, InveniAI will use its proprietary platform for the identification of potential pharmaceutical product opportunities using its Pharma Big Data Innovation Lab.

              Lead Product(s): Undisclosed

              Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Bristol Myers Squibb

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InveniAI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

              Details:

              The objective of the collaboration is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can be applied to generate compelling evidence for the role of G-protein coupled receptors (GPCRs) in relevant immunomodulatory pathways.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Sosei Heptares

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InveniAI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration

              Details:

              Through this expansion, Kyowa Kirin will leverage AlphaMeld® for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies. Under the terms of the agreement, Kyowa Kirin will select multiple programs to advance into clinical development.

              Lead Product(s): Monoclonal antibodies

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kyowa Kirin

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration December 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY